See us at Medica  2008 in partnership with Lynton Lasers, LumaCare's UK Distributor. Show Dates 19 - 22 November, 2008

LumaCare will be sponsoring the 28th Annual VCS Conference in Seattle Washington, at the Westin  OCT 18- 21, 2008

American Academy of Dermatology - 66th Annual Meeting - February 1-5, 2008
San Antonio, TX


+1 949 644 0126

USA Address:
P.O. Box 2024,
Newport Beach, CA 92659


Our LumaCare™ patented portfolio includes non-coherent light source for use in the field of Photodynamic Therapy (PDT). These cutting-edge technologies are vital to the commercial success of the PDT market. LumaCare™ light sources provide all the light-activation capabilities required by PDT drug protocols at a far lower cost than any competing light-activation sources, primarily lasers.

As drug companies continue their research in PDT, and with more protocols, drug-disease treatment procedures, advancing into the FDA Approval process, it becomes obvious that relying on lasers as the drugs light-activation source is the single highest expense facing the rapid market growth required for a positive revenue source to the pharmaceutical developers. For example, the most inexpensive laser system currently available for the approved photo-activated drug Photofrin® sells for approximately $45,000. Further, the FDA facility and operational rules add to this capital cost.

In addition to the acquisition cost are training costs for personnel to operate the lasers in the clinical environment. These specially trained laser personnel must be involved in the clinical uses of the PDT drugs. Further, there are numerous FDA-mandated rules associated with the laser-based system. Such operational requirements increase the overall costs of the PDT medical procedure and impede the widespread use of these new protocols.

Many of the universities and medical research centers involved in the initial drug protocol testing already owned an operational laser system with trained personnel and consequently did not need to design cost effective activation equipment. Contrast this with the real world situation where almost all medical facilities, the targeted market for PDT drugs, do not possess lasers and would have to purchase lasers, build the facilities, and train personnel. These high start-up costs are severe obstacles to the widespread market acceptance of PDT drugs.

LumaCare™ Non-Coherent Light Sources eliminate both the high acquisition and operational costs of lasers while delivering the identical light activation required for approved drug protocols. With LumaCare™ light sources, no special personnel training or facility improvements are necessary.

The current LumaCare™ Model LC-122 starts at $5,000 end user price. The total price depends on features and flexibilities the drug protocol and the medical facility require. Clearly, the costs associated with equipment acquisition and operation for LumaCare™ devices are a fraction of that of laser systems.

From the operating standpoint, the cost of administering the drugs to patients is far less; the cost of laser-trained technicians is eliminated. Current medical facility personnel can be familiarized to handle LumaCare™ equipment. This means the PDT protocol can be moved out of the hospital environment and into the Practitioner's office. As this occurs hospital overhead charges are eliminated, delivery costs to patient are dramatically lowered, and the market for PDT is expanded. This last economic advantage is key to the acceptance and approval of new drug protocols by cost-conscious HMO's.

The LumaCare™ management team realizes even the best products need adequate resources to succeed in the market. To that end, we will offer investment opportunities to those investors who share our vision. In exchange for this investment, management will grant investors an investment position in the company.

All investments will be used to fund the current marketing program, continuing improvement efforts, growing the IP portfolio, and development of the next generation of patented LumaCare™ light sources.

The potential market for LumaCare™ lamps is substantial; a result of the tremendous market potential for PDT drugs, particularly in the areas of dermatology, oncology, optometry, dentistry, and acne. To date, large drug companies and their affiliates have spent well over a half-billion dollars in PDT research. As PDT drugs continue to grow in acceptance and usage, there will be a huge demand for light-activation sources. The demand for the LumaCare™ lamps will grow to thousands of units per year within a few years of the drug's release to the market.

Presently, LumaCare™ units are used worldwide at several academic universities and research clinics. LumaCare devices have been cited in numerous published research and conference proceedings, as well as in many specific drug protocols under development.

LumaCare™ offers two models, the LC122A and the LC122M. Both models are in stock and available for sale. LC122A and LC122M are available for basic research, protocol development, and are currently approved within the EU for patient use. Research institutions or private clinics wishing to pursue research in PDT protocols may purchase LumaCare™ devices with or without drug company sponsorship.

The LumaCare™ Company, founded in 1994, is funded by the existing management team and our parent company, MBG Technologies Inc. LumaCare™ is registered to do business in the United Kingdom and subject to the laws thereof.

Photofrin is a registered trade name of QLT PhotoTherapeutics.


Website Designed and Maintained by Rod Steel Designs
© 1996-2008 MBG Technologies